Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma
The original release is unavailable here.
Earlier from Tron
- PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels
- Nanopharmaceutics Announces Initiation of Clinical Study of Oral Tetrathiomolybdate Capsules in Breast Cancer Patients
- Nanopharmaceutics, Inc. (TGRP) Changes Corporate Name back to TRON Group, Inc. and forms wholly-owned Nanopharmaceutics Subsidiary
- Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa